Doravirine/lamivudine/tenofovir disoproxil

Doravirine/lamivudine/tenofovir disoproxil (brand name Delstrigo) is a fixed-dose combination drug for the treatment of HIV/AIDS.[1][2] It contains doravirine, lamivudine, and tenofovir disoproxil.[3][2] In the United States, it was approved by the Food and Drug Administration (FDA) in August 2018, for the treatment of HIV-1 infection.[3][4]

Doravirine/lamivudine/tenofovir disoproxil
Combination of
DoravirineNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesDelstrigo
Other namesMK-1439A
ATC code
Legal status
Legal status
Identifiers
KEGG

It is on the World Health Organization's List of Essential Medicines, which lists the safest and most effective medicines needed in a health system.[5]

References
  1. "Doravirine/lamivudine/tenofovir disoproxil fumarate". Adis Insight.
  2. Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687.
  3. "FDA Approves Merck's DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. 30 August 2018.
  4. "Delstrigo approval letter" (PDF). Food and Drug Administration (FDA). 30 August 2018. Retrieved 10 September 2019.
  5. "World Health Organization model list of essential medicines: 21st list 2019". 2019. hdl:10665/325771. Cite journal requires |journal= (help)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.